stay tuned:
elixi news from the
world

Phorbiplatin, a new “on-site” activated anti-tumor prodrug that effectively kills cancer cells minimizing damage to normal tissues.

Phorbiplatin, a new “on-site” activated anti-tumor prodrug that effectively kills cancer cells minimizing damage to normal tissues.

A new anti-cancer chemical compound was found capable of reducing tumour size and weight by up to two-thirds in laboratory tests done by researchers from the City University of Hong Kong that made results recently public.

The problem in the fight against cancer is that the drugs used in chemotherapy are not controllably activated. Like a shotgun, they can impact the growth of a malignant tumour but in the process impair healthy cells

Most of the current clinical anti-tumor drugs used in chemotherapy move around in the patient’s blood after intake and are unable to pinpoint the targeted tumor. Aiming to overcome this problem, Dr Zhu Guangyu, Associate Professor of Department of Chemistry, City University of Hong Kong (CityU) and his research team have recently developed phorbiplatin , an anti-cancer prodrug that can be controllably activated by red light. With its unique “on-site” activation characteristic, it will effectively kill cancer cells and minimize damage to normal tissues.

Phorbiplatin is a small-molecule platinum(IV) anti-cancer prodrug, shown to be inert in the dark but can be activated under low-power red-light irradiation. “Under short-period irradiation with low intensity of red light (650 nm, 7 mW/cm2) and without any external catalyst, phorbiplatin is reduced to oxaliplatin, a first-line clinical chemotherapeutic drug, as well as pyropheophorbide a (PPA), a photoactivation ligand. Both substances are effective in killing tumor cells,” Dr Zhu explained the controllable activation property.

“Phorbiplatin is the first small-molecule platinum(IV) prodrug that can be activated by a red light,” he added.

Previously, researchers utilized ultraviolet light to activate small-molecule platinum anti-tumor drugs. However, ultraviolet light has poor penetration depth and can also damage cells. On the contrary, “red light does not harm normal cells. And it possesses higher penetration depth through the skin to reach the subcutaneous tumor,” Dr Zhu explained.

It took the team around 3 years to discover and study phorbiplatin, which is scaffolded on the molecular structure of oxaliplatin, a first-line anti-tumor drug widely used in the treatment of different cancers. The team functionlized oxaliplatin with PPA, which is a photosensitizer in photodynamic therapy and highly sensitive to red light, as the photoactive ligand to obtain phorbiplatin. Under irradiation with low intensity of red light, PPA acts as a “photo-induced redox relay” to transfer electrons from reducing agents to the platinum(IV) center to facilitate the reduction process, and as a result, releasing oxaliplatin.

The team also found that platinum-sensitive (A2780) human ovarian cancer cells treated with phorbiplatin under red light irradiation showed high fractions (68.0%) of dead cells. Compared with oxaliplatin, phorbiplatin displayed a remarkable ability to kill human breast cancer cells (MCF-7) with up to a 1,786-fold increase in photocytotoxicity, and a 974-fold increase for platinum-resistant (A2780cisR) human ovarian cancer cells.

Moreover, phorbiplatin with irradiation significantly inhibited tumor growth in mice, with 67% reduction in tumor volume and 62% reduction in tumor weight compared with mice treated with oxaliplatin, PPA, and even a mixture of oxaliplatin and PPA. The body weight of the mice treated with phorbiplatin did not change significantly, highlighting its safety.

Dr Zhu suggested that the controllable activation property and superior anti-tumor activity of phorbiplatin significantly contribute to the development of photoactivatable anti-cancer prodrugs, especially platinum(IV) prodrugs that can be activated by red light, to reduce the adverse effects and conquer drug resistance of traditional platinum chemotherapy.

The research findings were published in the scientific journal Chem, titled “Phorbiplatin, a Highly Potent Pt(IV) Antitumor Prodrug That Can Be Controllably Activated by Red Light”.

For more information and fast delivery of the life-saving, latest FDA approved oncology drugs, please contact us at info@elixi-int.com

We are a Swiss pharmaceutical wholesaler, specialised in sourcing and delivering pharma products, medical devices and drugs from and to all over the world.

Share this article

Share on twitter
Tweet
Share on facebook
Share
Share on pinterest
Pin it
Share on linkedin
Share

SEE Also

we are specialized in the procurement and distribution of pharmaceutical products, medical devices all over the world

Stay Tuned

Subscribe to our newsletter

Contact us

ELIXI International SA

Vicolo Oldelli 1
6830 Chiasso / Switzerland
Email info@elixi-int.com
Phone/Fax +41 91 6822040

ELIXI International SA

Copyright 2019 ELIXI International SA.   |   All Rights Reserved   |   Privacy Policy   |   Cookie Policy   |   Credits ATG Suisse